529 related articles for article (PubMed ID: 25919696)
1. MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms.
Amankwatia EB; Chakravarty P; Carey FA; Weidlich S; Steele RJ; Munro AJ; Wolf CR; Smith G
Br J Cancer; 2015 Apr; 112(9):1480-90. PubMed ID: 25919696
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-497 inhibits tumor growth and increases chemosensitivity to 5-fluorouracil treatment by targeting KSR1.
Wang L; Jiang CF; Li DM; Ge X; Shi ZM; Li CY; Liu X; Yin Y; Zhen L; Liu LZ; Jiang BH
Oncotarget; 2016 Jan; 7(3):2660-71. PubMed ID: 26673620
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells.
Nishida N; Yamashita S; Mimori K; Sudo T; Tanaka F; Shibata K; Yamamoto H; Ishii H; Doki Y; Mori M
Ann Surg Oncol; 2012 Sep; 19(9):3065-71. PubMed ID: 22322955
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of microRNA-135b and microRNA-182 promotes chemoresistance of colorectal cancer by targeting ST6GALNAC2 via PI3K/AKT pathway.
Liu B; Liu Y; Zhao L; Pan Y; Shan Y; Li Y; Jia L
Mol Carcinog; 2017 Dec; 56(12):2669-2680. PubMed ID: 28767179
[TBL] [Abstract][Full Text] [Related]
5. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
[TBL] [Abstract][Full Text] [Related]
6. Regulation of microRNA-1288 in colorectal cancer: altered expression and its clinicopathological significance.
Gopalan V; Pillai S; Ebrahimi F; Salajegheh A; Lam TC; Le TK; Langsford N; Ho YH; Smith RA; Lam AK
Mol Carcinog; 2014 Feb; 53 Suppl 1():E36-44. PubMed ID: 24009195
[TBL] [Abstract][Full Text] [Related]
7. Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy.
Manceau G; Imbeaud S; Thiébaut R; Liébaert F; Fontaine K; Rousseau F; Génin B; Le Corre D; Didelot A; Vincent M; Bachet JB; Chibaudel B; Bouché O; Landi B; Bibeau F; Leroy K; Penault-Llorca F; Van Laethem JL; Demetter P; Tejpar S; Rossi S; Mosakhani N; Osterlund P; Ristamäki R; Sarhadi V; Knuutila S; Boige V; André T; Laurent-Puig P
Clin Cancer Res; 2014 Jun; 20(12):3338-47. PubMed ID: 24771647
[TBL] [Abstract][Full Text] [Related]
8. MiR-22 regulates 5-FU sensitivity by inhibiting autophagy and promoting apoptosis in colorectal cancer cells.
Zhang H; Tang J; Li C; Kong J; Wang J; Wu Y; Xu E; Lai M
Cancer Lett; 2015 Jan; 356(2 Pt B):781-90. PubMed ID: 25449431
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-587 antagonizes 5-FU-induced apoptosis and confers drug resistance by regulating PPP2R1B expression in colorectal cancer.
Zhang Y; Talmon G; Wang J
Cell Death Dis; 2015 Aug; 6(8):e1845. PubMed ID: 26247730
[TBL] [Abstract][Full Text] [Related]
10. GDPD5, a target of miR-195-5p, is associated with metastasis and chemoresistance in colorectal cancer.
Feng C; Zhang L; Sun Y; Li X; Zhan L; Lou Y; Wang Y; Liu L; Zhang Y
Biomed Pharmacother; 2018 May; 101():945-952. PubMed ID: 29635904
[TBL] [Abstract][Full Text] [Related]
11. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue.
Mostert B; Jiang Y; Sieuwerts AM; Wang H; Bolt-de Vries J; Biermann K; Kraan J; Lalmahomed Z; van Galen A; de Weerd V; van der Spoel P; Ramírez-Moreno R; Verhoef C; Ijzermans JN; Wang Y; Gratama JW; Foekens JA; Sleijfer S; Martens JW
Int J Cancer; 2013 Jul; 133(1):130-41. PubMed ID: 23233388
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF.
Mosakhani N; Lahti L; Borze I; Karjalainen-Lindsberg ML; Sundström J; Ristamäki R; Osterlund P; Knuutila S; Sarhadi VK
Cancer Genet; 2012 Nov; 205(11):545-51. PubMed ID: 23098991
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA profiling differentiates colorectal cancer according to KRAS status.
Mosakhani N; Sarhadi VK; Borze I; Karjalainen-Lindsberg ML; Sundström J; Ristamäki R; Osterlund P; Knuutila S
Genes Chromosomes Cancer; 2012 Jan; 51(1):1-9. PubMed ID: 21922590
[TBL] [Abstract][Full Text] [Related]
14. Identification of microRNA-487b as a negative regulator of liver metastasis by regulation of KRAS in colorectal cancer.
Hata T; Mokutani Y; Takahashi H; Inoue A; Munakata K; Nagata K; Haraguchi N; Nishimura J; Hata T; Matsuda C; Murata K; Mizushima T; Doki Y; Mori M; Yamamoto H
Int J Oncol; 2017 Feb; 50(2):487-496. PubMed ID: 28000854
[TBL] [Abstract][Full Text] [Related]
15. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
[TBL] [Abstract][Full Text] [Related]
16. MiR-21 regulates biological behavior through the PTEN/PI-3 K/Akt signaling pathway in human colorectal cancer cells.
Xiong B; Cheng Y; Ma L; Zhang C
Int J Oncol; 2013 Jan; 42(1):219-28. PubMed ID: 23174819
[TBL] [Abstract][Full Text] [Related]
17. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
Schwartzberg LS; Rivera F; Karthaus M; Fasola G; Canon JL; Hecht JR; Yu H; Oliner KS; Go WY
J Clin Oncol; 2014 Jul; 32(21):2240-7. PubMed ID: 24687833
[TBL] [Abstract][Full Text] [Related]
18. Syndecan-2, negatively regulated by miR-20b-5p, contributes to 5-fluorouracil resistance of colorectal cancer cells via the JNK/ERK signaling pathway.
Hua R; Zhang Y; Yan X; Tang D; Li X; Ni Q; Wang D; Zhu J
Acta Biochim Biophys Sin (Shanghai); 2021 Nov; 53(11):1547-1557. PubMed ID: 34596215
[TBL] [Abstract][Full Text] [Related]
19. The interplay between epigenetic silencing, oncogenic KRas and HIF-1 regulatory pathways in control of BNIP3 expression in human colorectal cancer cells.
Swiderek E; Kalas W; Wysokinska E; Pawlak A; Rak J; Strzadala L
Biochem Biophys Res Commun; 2013 Nov; 441(4):707-12. PubMed ID: 24211581
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of NEK2 by microRNA-128 methylation is associated with poor prognosis in colorectal cancer.
Takahashi Y; Iwaya T; Sawada G; Kurashige J; Matsumura T; Uchi R; Ueo H; Takano Y; Eguchi H; Sudo T; Sugimachi K; Yamamoto H; Doki Y; Mori M; Mimori K
Ann Surg Oncol; 2014 Jan; 21(1):205-12. PubMed ID: 24046120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
